Brought to you by 
Alphamab grants Ascletis rights to HBV candidate in Greater China; Expand their Partnership into Worldwide License Agreement
08 Nov 2021
Executive Summary
Alphamab Co. Ltd. licensed Ascletis Pharma Inc. exclusive rights to develop and commercialize KN035 (renamed ASC22) in China, Hong Kong, Macau, and Taiwan for viral diseases, including hepatitis B.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alphamab grants Ascletis rights to HBV candidate in Greater China; Expand their Partnership into Worldwide License Agreement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice